Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiovascular Risk in NAFLD
Author(s): Paula Luque-Linero , Jose M Guerra Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Obesity Management and Cardiovascular Disease
Author(s): Miao Gao , Tanjot Singh , Ramzi Ajjan Added: 4 days ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
ACC 26: AI-Based Retinal Imaging for Atherosclerotic Cardiovascular Risk
Author(s): Michael McConnell Added: 1 week ago
ACC.26 – Dr Michael McConnell (Stanford Health Care, Stanford, CA, US) joins us to discuss findings from a prospective, multicentre clinical trial evaluating whether artificial intelligence analysis of retinal images can identify patients at elevated atherosclerotic cardiovascular risk.Findings showed strong sensitivity and specificity in identifying those at risk of ASCVD in a diverse study… View more

Prevention & Chronic Conditions

Digital Health
Symptomology, Outcomes and Risk Factors of Acute Coronary Syndrome Presentations without Cardiac Chest Pain: A Scoping Review
Author(s): Meriem Perona , Amanda Cooklin , Christopher Thorpe , et al Added: 1 year ago

MI/ACS
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 12 months ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
SOUL: Oral Semaglutide Aids CV Risk in T2D
Added: 2 weeks ago Source:  Radcliffe CVRM
Individuals with type 2 diabetes (T2D) face a high risk of atherosclerotic cardiovascular disease (ASCVD). The SOUL trial (NCT03914326) previously demonstrated that oral semaglutide reduced major adverse cardiovascular events (MACE).² A new post hoc secondary analysis of this trial now provides insight into the mechanisms behind this benefit, detailing the drug's association with changes in key… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Author(s): Evan A Stein Added: 2 years ago
ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period… View more

Prevention & Chronic Conditions
Targeted Lipid Control in Very-high-risk Indian Patients: Expert Insights
Author(s): Kausik Ray , Upendra Kaul , Srinivasa Rao , et al Added: 4 months ago

Guidelines & Statements
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 4 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
Sudden Cardiac Death Risk in Newly Diagnosed Heart Failure: SCD-PROTECT
Author(s): Marat Fudim , David Duncker Added: 1 month ago
In this episode of Arrhythmia Academy's Journal Club, Dr David Duncker (Hannover Heart Rhythm Center, DE) is joined by Dr Marat Fudim (Duke University, US) to examine the critical early-risk period following heart failure diagnosis and the emerging role of wearable cardioverter defibrillators in sudden cardiac death prevention.The discussion centres on findings from the SCD-PROTECT study, a 19… View more

Electrophysiology & Arrhythmia

Heart Failure